title: The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study.
abstract: OBJECTIVE
  To identify the minimum effective single oral dose of metronidazole for trichomoniasis.
  
  
  METHODS
  Women attending an inner-city sexually transmitted disease clinic who had Trichomonas vaginalis vaginitis diagnosed by microscopy were recruited for this randomized, double-blind study. Subjects were given a 0.5-, 1-, 1.5-, or 2-g single oral dose of metronidazole, taken under direct observation. Demographic information, symptoms, and clinical findings were collected from patient interviews, and physical examinations were conducted at the time of enrollment and at the follow-up visit. The primary outcome measure was treatment success at the follow-up visit, established by negative culture and microscopy.
  
  
  RESULTS
  Three (1.8%) of the 167 women enrolled were excluded because of vomiting after taking metronidazole, and 66 (40%) of the 164 remaining subjects did not return for the follow-up visit. No associations were found between the proportion of subjects lost to follow-up and the characteristics of these subjects across assignment groups. The treatment success ratio was highest in subjects who received the 1.5-g dose (23, 85%), followed by the 2-g (16, 84%), 1-g (18, 62%), and the 0.5-g dose (8, 35%).
  
  
  CONCLUSIONS
  A single 1.5-g dose of metronidazole has efficacy equivalent to a single 2-g dose for the treatment of T vaginalis vaginitis.
authors.affiliation: Department of Community and Preventive Medicine, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Spence
authors.forename: T S
authors.initials: TS
authors.lastname: Harwell
authors.forename: M C
authors.initials: MC
authors.lastname: Davies
authors.forename: J L
authors.initials: JL
authors.lastname: Smith
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000994:Antitrichomonal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014247:Trichomonas Vaginitis / Q000188:drug therapy* / Q000469:parasitology; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000994:Antitrichomonal Agents; D008795:Metronidazole